(Q41546485)

3 October 2017

title

Hepatitis C virus treatment as prevention among injecting drug users: who should we cure first? (English)

1 reference

3 October 2017

1 reference

2

Maria Prins

1 reference

3 October 2017

Anneke S de Vos

1

1 reference

3 October 2017

Mirjam E E Kretzschmar

series ordinal

3

1 reference

3 October 2017

language of work or name

English

0 references

publication date

8 February 2015

1 reference

3 October 2017

1 reference

3 October 2017

volume

110

1 reference

3 October 2017

issue

6

1 reference

3 October 2017

page(s)

975-983

1 reference

Best strategies for global HCV eradication

3 October 2017

cites work

1 reference

Hepatitis C treatment for injection drug users: a review of the available evidence

21 January 2018

1 reference

Hepatitis C testing and treatment among active drug users in Amsterdam: results from the DUTCH-C project

21 January 2018

1 reference

Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis

21 January 2018

1 reference

Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model

21 January 2018

1 reference

Treatment as prevention and cure towards global eradication of hepatitis C virus

21 January 2018

1 reference

Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia

21 January 2018

1 reference

Optimal targeting of Hepatitis C virus treatment among injecting drug users to those not enrolled in methadone maintenance programs

21 January 2018

1 reference

Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals

21 January 2018

1 reference

Optimal control of hepatitis C antiviral treatment programme delivery for prevention amongst a population of injecting drug users

21 January 2018

1 reference

Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations

21 January 2018

1 reference

HCV direct-acting antiviral agents: the best interferon-free combinations

21 January 2018

1 reference

Elimination on the agenda for hepatitis C.

21 January 2018

1 reference

Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: feasibility and future requirements

21 January 2018

1 reference

Can hepatitis C virus infection be eradicated in people who inject drugs?

21 January 2018

1 reference

Benefits of hepatitis C virus treatment: a balance of preventing onward transmission and re-infection

21 January 2018

1 reference

Determinants of persistent spread of HIV in HCV-infected populations of injecting drug users

21 January 2018

1 reference

Prospective follow-up of patients with acute hepatitis C virus infection in Brazil.

21 January 2018

1 reference

Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies

21 January 2018

1 reference

Modelling the impact on Hepatitis C transmission of reducing syringe sharing: London case study.

21 January 2018

1 reference

Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection

21 January 2018

1 reference

Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine

21 January 2018

1 reference

Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion

21 January 2018

1 reference

Distributive syringe sharing among young adult injection drug users in five U.S. cities

21 January 2018

1 reference

Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users

21 January 2018

1 reference

Prevalence of HIV-infected syringes during a syringe-exchange program

21 January 2018

1 reference

Surveillance of HIV, hepatitis B virus, and hepatitis C virus in an estonian injection drug-using population: sensitivity and specificity of testing syringes for public health surveillance

21 January 2018

1 reference

Hepatitis C virus reinfection following treatment among people who use drugs

21 January 2018

1 reference

Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial

21 January 2018

1 reference

The efficiency of targeted intervention in limiting the spread of HIV and Hepatitis C Virus among injecting drug users

21 January 2018

1 reference

Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study

21 January 2018

1 reference

Trajectories of injection drug use over 20 years (1988-2008) in Baltimore, Maryland

21 January 2018

1 reference

Trajectories of heroin addiction: growth mixture modeling results based on a 33-year follow-up study

21 January 2018

1 reference

Trajectories of injecting behavior in the Amsterdam Cohort Study among drug users

21 January 2018

1 reference

Can Hepatitis C virus treatment be used as a prevention strategy? Additional model projections for Australia and elsewhere

21 January 2018

1 reference

Shooting gallery attendance among IDUs in Tijuana and Ciudad Juarez, Mexico: correlates, prevention opportunities, and the role of the environment

21 January 2018

1 reference

Injecting drug users with chronic hepatitis C: should they be offered antiviral therapy?

21 January 2018

1 reference

Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/ADD.12842

1 reference

3 October 2017

1 reference